NCT02386618

Endoscopic Treatment for Local Residual Neoplasia

Endoscopic Treatment for Local Residual Neoplasia After Endoscopic Mucosal Resection of the Colorectal Lateral Spreading Tumors (LST)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Vitkovice Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Endoscopic mucosal resection (EMR) is considered to be a gold standard of therapy of colorectal lateral spreading tumors (LST) without significant risk for lymphatic spread. According to the investigators previous study, local residual neoplasia (LRN) after conventional endoscopic mucosal resection (EMR)occurs in up to 21% of cases. Endoscopic therapy of LRN was not sufficient in 53 % and has not been standardized yet.

Conditions

• Colorectal Cancer

Interventions

Type	Name	Description
PROCEDURE	Standardized endoscopic treatment of local residual neoplasia	Endoscopic treatment will be performed according to the type of local residual neoplasia (LRN): A - endoscopically negative scar and neoplastic tissue found only in biopsy specimens - treatment by argon plasmacoagulation, B - endoscopically aparent LRN \< 5 mm - forceps biopsy + argon plasmacoagulation, C - endoscopically evident LRN \> 5 mm + lifting during submucosal injection - endoscopic mucosal resectio + argon plasmacoagulation, D - endoscopically evident LRN \> 5 mm + non-lifting during submucosal injection - endoscopic submucosal disection (ESD) or surgical resection

Timeline

• Start date: 2013-10-01
• Primary completion: 2015-06-01
• Completion: 2015-06-01
• First posted: 2015-03-12
• Last updated: 2015-10-06

Locations

1 site across 1 country: Czechia